EMQN Best Practice Guidelines for Genetic Testing and Reporting in RYR1-related disorders

Area of Science:

• Genetics
• Molecular Biology
• Clinical Diagnostics

Background:

• The ryanodine receptor type 1 (RYR1) gene encodes a critical calcium channel in skeletal muscle.
• Pathogenic variants in RYR1 are linked to diverse neuromuscular disorders, including malignant hyperthermia, exertional rhabdomyolysis, and congenital myopathies.
• Interpreting RYR1 variants is complex due to genotype-phenotype discrepancies and context-dependent disease associations.

Purpose of the Study:

• To establish EMQN Best Practice Guidelines for genetic testing and reporting of RYR1 variants.
• To provide clear recommendations for clinical genetic laboratories to ensure accurate and comprehensive variant analysis.
• To aid in the diagnosis and management of patients with RYR1-related disorders and their families.

Main Methods:

• Guidelines developed by a multidisciplinary expert panel including anaesthetists, neurologists, and geneticists.
• Focus on best practices for genetic testing methodologies and variant interpretation.
• Emphasis on standardized reporting of RYR1 variants.

Main Results:

• The guidelines address the challenges in RYR1 variant interpretation, particularly concerning genotype-phenotype correlations.
• They aim to standardize the reporting of RYR1 variants to improve diagnostic accuracy.
• The guidelines facilitate risk assessment for patients and relatives, crucial for family planning.

Conclusions:

• Adherence to these best practice guidelines will enhance the quality and consistency of genetic testing for RYR1 disorders.
• Standardized reporting improves diagnostic yield and aids in understanding the complex relationship between RYR1 variants and clinical phenotypes.
• These guidelines are essential for optimizing patient care and genetic counseling in RYR1-related conditions.